Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Neurocrine Biosciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Neurocrine Biosciences's price to book ratio was 4.8× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 3.9× to 7.9×, with a median of 5.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.8× | +0.1 |
| 2025 | Dec 31, 2025 | 4.7× | −0.4 |
| 2024 | Dec 31, 2024 | 5.1× | −1.4 |
| 2023 | Dec 29, 2023 | 6.5× | −1.0 |
| 2022 | Dec 30, 2022 | 7.4× | +1.4 |
| 2021 | Dec 31, 2021 | 6.0× | −5.1 |
| 2020 | Dec 31, 2020 | 11.1× | −6.1 |
| 2019 | Dec 31, 2019 | 17.2× | +2.8 |
| 2018 | Dec 31, 2018 | 14.5× | −5.3 |
| 2017 | Dec 29, 2017 | 19.8× | +10.2 |
| 2016 | Dec 30, 2016 | 9.6× | −1.3 |
| 2015 | Dec 31, 2015 | 10.9× | +3.3 |
| 2014 | Dec 31, 2014 | 7.6× | +2.7 |
| 2013 | Dec 31, 2013 | 4.9× | +1.4 |
| 2012 | Dec 31, 2012 | 3.5× | −4.7 |
| 2011 | Dec 30, 2011 | 8.1× | −67.5 |
| 2010 | Dec 31, 2010 | 75.6× | – |
See a number that looks wrong?